Tesla
TSLA
NVIDIA
NVDA
Advanced Micro Devices
AMD
Taiwan Semiconductor
TSM
Micron Technology
MU
US Stock MarketDetailed Quotes
YTENQ Yield10 Bioscience
- 0.350
- 0.0000.00%
15min DelayClose Jan 3 16:00 ET
242.37KMarket Cap-0.02P/E (TTM)
0.350High0.350Low1.08KVolume0.350Open0.350Pre Close379.29Turnover0.17%Turnover RatioLossP/E (Static)692.68KShares17.25652wk High-0.04P/B217.76KFloat Cap0.20252wk Low--Dividend TTM622.35KShs Float1714176.000Historical High--Div YieldTTM0.00%Amplitude0.202Historical Low0.349Avg Price1Lot Size
Yield10 Bioscience News
Express News | Yield10 Bioscience Inc - Files for Chapter 11 Bankruptcy
Yield10 Bioscience Announces Adjournment of Special Meeting of Stockholders to Solicit Sufficient Votes in Favor of the Key Proposals
Yield10 Bioscience Announces Asset Sale and Planned Dissolution
Yield10 Bioscience GAAP EPS of -$5.04 Misses by $4.01
Yield10 Bioscience 2Q Loss/Shr $5.04 >YTEN
Express News | Yield10 Bioscience Announces Second Quarter 2024 Financial Results
Yield10 Bioscience | 10-Q: Q2 2024 Earnings Report
Yield10 Bioscience Settles Convertible Note Early for $500K
Express News | Yield10 Bioscience Grants Nufarm a Commercial License to Omega-3 Assets for Producing Oil in Camelina, and Yield10 and Nufarm Sign a Memorandum of Understanding for Sale of Assets
Delisting of Securities of CONX Corp.; Priveterra Acquisition Corp. II; Yield10 Bioscience, Inc.; Aesthetic Medical International Holdings Group Ltd.; Breeze Holdings Acquisition Corp.; Quadro Acquisition One Corp.; DermTech, Inc.; TRACON...
Rothamsted Research Grants Yield10 Bioscience an Exclusive, Global Commercial License to Advanced Technology for Producing Omega-3 Products in Camelina
Yield10 Bioscience Announces Addition of Camelina to INTERLINE Herbicide Label
Hold Rating on Yield10 Bioscience Amid Commercialization Challenges and Financial Uncertainties
Yield10 Bioscience(YTEN.US) 10% Shareholder Sells US$7,200 in Common Stock
$Yield10 Bioscience(YTEN.US)$ 10% Shareholder SCHULER JACK W sold 36,000 shares of common stock on Dec 20, 2023 at an average price of $0.2 for a total value of $7,200.Source: Announcement What is sta
Yield10 Bioscience: A Cautious Hold Amid Financial Uncertainty and Strategic Potential
Yield10 Bioscience (YTEN.US): The 2024 Q1 financial report achieved revenue of 300,000 US dollars, previous value of 60,000 US dollars, expected value of 1.87 million US dollars; earnings per share were -4.77 US dollars, previous value was -18.16 US dolla
Yield10 Bioscience (YTEN.US): The 2024 Q1 financial report achieved revenue of 300,000 US dollars, previous value of 60,000 US dollars, expected value of 1.87 million US dollars; earnings per share were -4.77 US dollars, previous value was -18.16 US dollars, and expected value was -2.64 US dollars.
Yield10 Bioscience | 8-K: Yield10 Bioscience Announces First Quarter 2024 Financial Results
Yield10 Bioscience | 10-Q: Q1 2024 Earnings Report
Earnings Flash (YTEN) YIELD10 BIOSCIENCE Posts Q1 Revenue $300,000
Yield10 Bioscience Q1 2024 Adj EPS $(4.77) Misses $(2.64) Estimate, Sales $300.00K Miss $1.88M Estimate
Trending US Stocks
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.